Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade
The aim of this retrospective study is to provide real-world evidence in glioblastoma treatment and to compare overall survival after Stupp's regimen treatment today and a decade ago. A current consecutive cohort of histologically confirmed glioblastoma irradiated from 1/2014 to 12/2017 in our...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00840/full |
| _version_ | 1828400288430555136 |
|---|---|
| author | Radek Lakomy Radek Lakomy Tomas Kazda Tomas Kazda Tomas Kazda Iveta Selingerova Alexandr Poprach Alexandr Poprach Petr Pospisil Petr Pospisil Renata Belanova Renata Belanova Pavel Fadrus Vaclav Vybihal Martin Smrcka Radim Jancalek Ludmila Hynkova Ludmila Hynkova Katarina Muckova Michal Hendrych Jiri Sana Jiri Sana Jiri Sana Ondrej Slaby Ondrej Slaby Ondrej Slaby Pavel Slampa Pavel Slampa |
| author_facet | Radek Lakomy Radek Lakomy Tomas Kazda Tomas Kazda Tomas Kazda Iveta Selingerova Alexandr Poprach Alexandr Poprach Petr Pospisil Petr Pospisil Renata Belanova Renata Belanova Pavel Fadrus Vaclav Vybihal Martin Smrcka Radim Jancalek Ludmila Hynkova Ludmila Hynkova Katarina Muckova Michal Hendrych Jiri Sana Jiri Sana Jiri Sana Ondrej Slaby Ondrej Slaby Ondrej Slaby Pavel Slampa Pavel Slampa |
| author_sort | Radek Lakomy |
| collection | DOAJ |
| description | The aim of this retrospective study is to provide real-world evidence in glioblastoma treatment and to compare overall survival after Stupp's regimen treatment today and a decade ago. A current consecutive cohort of histologically confirmed glioblastoma irradiated from 1/2014 to 12/2017 in our cancer center was compared with an already published historical control of patients treated in 1/2003–12/2009. A total of new 155 patients was analyzed, median age 60.9 years, 61% men, 58 patients (37%) underwent gross total tumor resection. Stupp's regimen was indicated in 90 patients (58%), 65 patients (42%) underwent radiotherapy alone. Median progression-free survival in Stupp's regimen cohort was 6.7 months, median OS 16.0 months, and 2-year OS 30.7%. OS was longer if patients were able to finish at least three cycles of adjuvant chemotherapy (median 23.3 months and 43.9% of patients lived at 2 years after surgery). Rapid early progression prior to radiotherapy was a negative prognostic factor with HR 1.87 (p = 0.007). The interval between surgery and the start of radiotherapy (median 6.7 weeks) was not prognostically significant (p = 0.825). The median OS in the current cohort was about 2 months longer than in the historical control group treated 10 years ago (16 vs. 13.8 months) using the same Stupp's regimen. Taking into account differences in patient's characteristics between current and historical cohorts, age, extent of resection, and ECOG patient performance status adjusted HR (Stupp's regimen vs. RT alone) for OS was determined as 0.45 (p = 0.002). |
| first_indexed | 2024-12-10T09:30:05Z |
| format | Article |
| id | doaj.art-1d0758fd945243c3bb797cdae45d2383 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-10T09:30:05Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1d0758fd945243c3bb797cdae45d23832022-12-22T01:54:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-07-011010.3389/fonc.2020.00840545340Real-World Evidence in Glioblastoma: Stupp's Regimen After a DecadeRadek Lakomy0Radek Lakomy1Tomas Kazda2Tomas Kazda3Tomas Kazda4Iveta Selingerova5Alexandr Poprach6Alexandr Poprach7Petr Pospisil8Petr Pospisil9Renata Belanova10Renata Belanova11Pavel Fadrus12Vaclav Vybihal13Martin Smrcka14Radim Jancalek15Ludmila Hynkova16Ludmila Hynkova17Katarina Muckova18Michal Hendrych19Jiri Sana20Jiri Sana21Jiri Sana22Ondrej Slaby23Ondrej Slaby24Ondrej Slaby25Pavel Slampa26Pavel Slampa27Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, CzechiaDepartment of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, CzechiaDepartment of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, CzechiaResearch Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, CzechiaResearch Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, CzechiaDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, CzechiaDepartment of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, CzechiaDepartment of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Radiology, Masaryk Memorial Cancer Institute, Brno, CzechiaFaculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Neurosurgery, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Neurosurgery, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Neurosurgery, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Neurosurgery, St. Anne's University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, CzechiaDepartment of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czechia0Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia1First Department of Pathology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, CzechiaDepartment of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czechia0Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, CzechiaDepartment of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czechia0Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, CzechiaDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, CzechiaDepartment of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, CzechiaThe aim of this retrospective study is to provide real-world evidence in glioblastoma treatment and to compare overall survival after Stupp's regimen treatment today and a decade ago. A current consecutive cohort of histologically confirmed glioblastoma irradiated from 1/2014 to 12/2017 in our cancer center was compared with an already published historical control of patients treated in 1/2003–12/2009. A total of new 155 patients was analyzed, median age 60.9 years, 61% men, 58 patients (37%) underwent gross total tumor resection. Stupp's regimen was indicated in 90 patients (58%), 65 patients (42%) underwent radiotherapy alone. Median progression-free survival in Stupp's regimen cohort was 6.7 months, median OS 16.0 months, and 2-year OS 30.7%. OS was longer if patients were able to finish at least three cycles of adjuvant chemotherapy (median 23.3 months and 43.9% of patients lived at 2 years after surgery). Rapid early progression prior to radiotherapy was a negative prognostic factor with HR 1.87 (p = 0.007). The interval between surgery and the start of radiotherapy (median 6.7 weeks) was not prognostically significant (p = 0.825). The median OS in the current cohort was about 2 months longer than in the historical control group treated 10 years ago (16 vs. 13.8 months) using the same Stupp's regimen. Taking into account differences in patient's characteristics between current and historical cohorts, age, extent of resection, and ECOG patient performance status adjusted HR (Stupp's regimen vs. RT alone) for OS was determined as 0.45 (p = 0.002).https://www.frontiersin.org/article/10.3389/fonc.2020.00840/fullglioblastomachemotherapyradiotherapyrapid early progressionoverall survivalreal-world evidence |
| spellingShingle | Radek Lakomy Radek Lakomy Tomas Kazda Tomas Kazda Tomas Kazda Iveta Selingerova Alexandr Poprach Alexandr Poprach Petr Pospisil Petr Pospisil Renata Belanova Renata Belanova Pavel Fadrus Vaclav Vybihal Martin Smrcka Radim Jancalek Ludmila Hynkova Ludmila Hynkova Katarina Muckova Michal Hendrych Jiri Sana Jiri Sana Jiri Sana Ondrej Slaby Ondrej Slaby Ondrej Slaby Pavel Slampa Pavel Slampa Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade Frontiers in Oncology glioblastoma chemotherapy radiotherapy rapid early progression overall survival real-world evidence |
| title | Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade |
| title_full | Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade |
| title_fullStr | Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade |
| title_full_unstemmed | Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade |
| title_short | Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade |
| title_sort | real world evidence in glioblastoma stupp s regimen after a decade |
| topic | glioblastoma chemotherapy radiotherapy rapid early progression overall survival real-world evidence |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.00840/full |
| work_keys_str_mv | AT radeklakomy realworldevidenceinglioblastomastuppsregimenafteradecade AT radeklakomy realworldevidenceinglioblastomastuppsregimenafteradecade AT tomaskazda realworldevidenceinglioblastomastuppsregimenafteradecade AT tomaskazda realworldevidenceinglioblastomastuppsregimenafteradecade AT tomaskazda realworldevidenceinglioblastomastuppsregimenafteradecade AT ivetaselingerova realworldevidenceinglioblastomastuppsregimenafteradecade AT alexandrpoprach realworldevidenceinglioblastomastuppsregimenafteradecade AT alexandrpoprach realworldevidenceinglioblastomastuppsregimenafteradecade AT petrpospisil realworldevidenceinglioblastomastuppsregimenafteradecade AT petrpospisil realworldevidenceinglioblastomastuppsregimenafteradecade AT renatabelanova realworldevidenceinglioblastomastuppsregimenafteradecade AT renatabelanova realworldevidenceinglioblastomastuppsregimenafteradecade AT pavelfadrus realworldevidenceinglioblastomastuppsregimenafteradecade AT vaclavvybihal realworldevidenceinglioblastomastuppsregimenafteradecade AT martinsmrcka realworldevidenceinglioblastomastuppsregimenafteradecade AT radimjancalek realworldevidenceinglioblastomastuppsregimenafteradecade AT ludmilahynkova realworldevidenceinglioblastomastuppsregimenafteradecade AT ludmilahynkova realworldevidenceinglioblastomastuppsregimenafteradecade AT katarinamuckova realworldevidenceinglioblastomastuppsregimenafteradecade AT michalhendrych realworldevidenceinglioblastomastuppsregimenafteradecade AT jirisana realworldevidenceinglioblastomastuppsregimenafteradecade AT jirisana realworldevidenceinglioblastomastuppsregimenafteradecade AT jirisana realworldevidenceinglioblastomastuppsregimenafteradecade AT ondrejslaby realworldevidenceinglioblastomastuppsregimenafteradecade AT ondrejslaby realworldevidenceinglioblastomastuppsregimenafteradecade AT ondrejslaby realworldevidenceinglioblastomastuppsregimenafteradecade AT pavelslampa realworldevidenceinglioblastomastuppsregimenafteradecade AT pavelslampa realworldevidenceinglioblastomastuppsregimenafteradecade |